“As someone who has been involved in Israel’s life sciences arena on the entrepreneurial side for quite a few years, I was interested in getting more involved in helping support the next generation of Israeli braintech companies,” explains Danny Weiss, who recently joined the IBT board of directors and also mentors at IBT’s Brainnovations accelerator program. “IBT is clearly a place where I feel I can make a significant impact, and I’m glad to have joined the team in the important work they do.”
Weiss is a life science entrepreneur and executive. He is currently the CEO of CardioLogic Innovations, he previously served as CEO of WellSense Technologies, and is active in several industry organizations. “The path to success in braintech, and in other arenas, is paved by ‘expertise.’ Through the Brainnovations accelerator, Braingels investor program, and of course the local and international events including the BrainTech Conference, IBT has become a leading expert and hub for the BrainTech industry. My other reason for joining IBT is the great team – it’s a pleasure to work with such a professional and dedicated group.”
As a board member, Weiss has been involved in defining IBT’s agenda and vision, as well as in actively supporting the industry. “One of the most exciting things happening now is the work we’re doing to launch an Israeli BrainTech Industry Association,” explains Weiss. Recently, senior leaders from 30 companies have come together and are working to establish this association. “With the potential to receive government funding, our ability to provide support to the industry will grow significantly,” says Weiss.
Weiss is also currently providing hand-on mentoring to startups, as a mentor in the second cycle of Brainnovations . Weiss is one of the mentors advising re:mind, a startup developing a home-based helmet which will be able to indicate if a stroke has occurred in order to ensure timely diagnosis and early treatment. “The first 4-5 hours after a stroke are critical, afterwards damage is very difficult to contain, so this solution could potentially have dramatic impact. I’m excited to be working with the team at re:mind,” says Weiss.
We also asked Weiss where the BrainTech industry is headed, and what the latest trends are. “There is a movement in the medical arena in general but also relevant to BrainTech, from treatment to prevention,” explains Weiss. In the past, the healthcare system focused on treatment rather than prevention, at a high cost to patients and society, both clinically and economically. Now there are a number of new laws like the Patient Protection and Affordable Care Act (PPACA) nicknamed “Obamacare’ which established the Hospital Readmissions Reduction Program penalizing hospitals for higher than expected readmission rates of certain medical conditions, incentivizing them to provide better care and prevent these readmissions. “This trend opens up potential for startups developing solutions in prevention, and should lead to a promising batch of companies and products,” concludes Weiss.